| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study was to address the mechanism of action responsible for the effect of CGRP on colitis and the possibility of a biomarker for IBD. The result was that CGRP effectively suppresses colonic injury through the down-regulation of pro-inflammatory cytokines and the up-regulation of protective events, including bone marrow-derived cell induction, in addition to promoting colonic blood flow. CGRP is an attractive therapeutic target and a novel biomarker for UC patients.
|
